irinotecan

E823218

Irinotecan is a chemotherapy drug, specifically a topoisomerase I inhibitor, commonly used to treat colorectal and other cancers.

Jump to: Statements Referenced by

Statements (50)

Predicate Object
instanceOf camptothecin derivative
chemotherapy drug
prodrug
topoisomerase I inhibitor
hasActiveMetabolite SN-38 NERFINISHED
hasApprovalYear 1996
hasATCCode L01CE02
hasBlackBoxWarningFor myelosuppression
severe diarrhea
hasCASNumber 97682-44-5
hasCommonSideEffect abdominal pain
alopecia
diarrhea
nausea
neutropenia
vomiting
hasEliminationRoute biliary excretion
fecal excretion
renal excretion
hasIndication advanced colorectal cancer
cervical cancer
gastric cancer
metastatic colorectal cancer
ovarian cancer
pancreatic cancer
small cell lung cancer
hasIUPACName (4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidinopiperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
hasMechanismOfAction inhibition of DNA topoisomerase I
hasMolecularFormula C33H38N4O6
hasOrigin semisynthetic derivative of camptothecin
hasPharmacologicClass antineoplastic agent
topoisomerase inhibitor
hasPregnancyCategory D (US, historical classification)
hasRouteOfAdministration intravenous
hasSeriousSideEffect severe diarrhea
severe neutropenia
isAdministeredBy intravenous infusion
isComponentOfRegimen FOLFIRI NERFINISHED
XELIRI NERFINISHED
isContraindicatedIn known hypersensitivity to irinotecan
severe bone marrow suppression
isInactivatedBy UGT1A1 NERFINISHED
isMetabolizedBy CYP3A4 NERFINISHED
CYP3A5 NERFINISHED
carboxylesterase enzymes
isProdrugOf SN-38 NERFINISHED
isSubstrateOf P-glycoprotein
isTeratogenic yes
targets DNA topoisomerase I
wasApprovedBy U.S. Food and Drug Administration NERFINISHED

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

aflibercept usedWith irinotecan